NASDAQ : CERC

Cerecor Inc.

$2.93 USD

-$0.05 (-1.68%)

Volume
258.59K
Average Volume
639.17K
Market Capitalization
$38.63M
P/E Ratio
-0.53
Dividend Yield
0.00%
Price Target
Year High
$4.50
Year Low
$1.98
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.66
Company Overview

NASDAQ

Michael Cola

Biotechnology

Healthcare

CERC

30

US

USD

http://www.cerecor.com

14105228707

15671L109

0001534120

Liquidity Metrics

0.00

7.66

7.66

2.15

0.00

Sales & Valuation

$59000

-184.83

0.86

-0.65

-2.97

Profitability

-$5.84

-$78.26M

46836.84%

46755.98%

-112.68%

-98.00%

P/E Metrics

-0.53

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

6 Analysts

%

Financial Health Scores

-6.89

1/9

$77.23M

$99.88M

$31.56M

-$60.15M

Key Metrics (TTM)

$13.64M

-65.27

-0.23

7.66

-112.68%

-89.66%

-166.16%

-154.52%

-970 days

Company Executives

No executive data available.

Poll Results

No votes yet today — be the first to share your view!

About Cerecor Inc. (NASDAQ:CERC) Stock

Cerecor Inc. operates as a biopharmaceutical firm dedicated to the discovery and marketing of therapeutic solutions, primarily addressing rare pediatric and orphan diseases. The company maintains an active pipeline, including: Inherited Metabolic Disorders: Advancing CERC-801 and CERC-802, both of which have successfully completed Phase I clinical trials, alongside CERC-803. Autoimmune Inflammatory Conditions: Developing CERC-007, an anti-IL-18 monoclonal antibody, designed to combat ailments such as adult-onset Still's disease and multiple myeloma. Complex Lymphatic Malformations: Progressing CERC-006, a dual mTOR inhibitor. Pediatric-onset Crohn's Disease: Working on CERC-002, an anti-LIGHT monoclonal antibody. Mitochondrial Disorders: Investigating CERC-913, a protide nucleotide. Rare A ... uto-inflammatory Diseases: Developing CERC-005, a monoclonal antibody. Symptomatic Orthostatic Hypotension: Pursuing CERC-301. Parkinson's Disease: Researching CERC-406. Beyond its research and development efforts, Cerecor also markets Millipred, an oral prednisolone formulation used to manage various inflammatory ailments. These include conditions affecting the joints (arthritis), blood, immune system, skin, eyes, respiratory system, as well as certain cancers and severe allergies. Established in 2011, when it rebranded from Ceregen Corporation to Cerecor Inc., the company's headquarters are situated in Rockville, Maryland.

Frequently Asked Questions

What is the current Cerecor Inc. (CERC) stock price?

Cerecor Inc.(NASDAQ:CERC) stock price is $2.93 in the last trading session. During the trading session, CERC stock reached the peak price of $2.98 while $2.9 was the lowest point it dropped to. The percentage change in CERC stock occurred in the recent session was --1.68% while the dollar amount for the price change in CERC stock was -$0.05.

CERC's industry and sector of operation?

The NASDAQ listed CERC is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CERC?

|
|
|
|
|

How many employees does CERC have?

Number of CERC employees currently stands at 30. CERC operates from 540 Gaither Rd Ste 400, Rockville, MD 20850, US.

Link for CERC official website?

Official Website of CERC is: http://www.cerecor.com

How do I contact CERC?

CERC could be contacted at phone #14105228707 and can also be accessed through its website. CERC operates from 540 Gaither Rd Ste 400, Rockville, MD 20850, US.

How many shares of CERC are traded daily?

The average number of CERC shares traded daily for last 3 months was 639.17K.

What is the market cap of CERC currently?

The market value of CERC currently stands at $38.63M with its latest stock price at $2.93